This page shows the latest axial spondyloarthritis news and features for those working in and with pharma, biotech and healthcare.
Bimzelx is now recommended to treat certain patients with psoriatic arthritis and axial spondyloarthritis, two forms of chronic inflammatory arthritis. ... adults with psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA).
Bimzelx is now approved to treat psoriatic arthritis and axial spondyloarthritis. ... PsA) and axial spondyloarthritis (axSpA).
Rinvoq is already approved to treat certain patients with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, ulcerative colitis and atopic dermatitis.
The drug is now approved to treat psoriatic arthritis and axial spondyloarthritis. ... The European Commission (EC) has granted UCB's Bimzelx (bimekizumab) two new approvals, with the inflammatory disease drug now authorised to treat certain adults with
The therapy is also already approved in the EU for adults with radiographic axial spondyloarthritis, non-radiographic axial spondyloarthritis, psoriatic arthritis, rheumatoid arthritis and ulcerative colitis, as well as for adults
Safety in this paediatric population was consistent with the known safety profile of Cosentyx for the treatment of adult and paediatric plaque psoriasis, PsA and axial spondyloarthritis, the company reported.
More from news
Approximately 5 fully matching, plus 17 partially matching documents found.
No results were found
We’re a specialist health consultancy that supports companies, healthcare professionals and patients to work hand in hand with a common...